Balbi G C, Compagna R, Musone R, Cirelli G, Sgambato R, Cassese E, Delli Ponti D, Passaro M, Zarcone R
Istituto di Clinica Ostetrica e Ginecologica, Seconda Università degli Studi, Napoli.
Minerva Ginecol. 2001 Feb;53(1 Suppl 1):105-9.
The aim of this study is to evaluate the efficacy of cytoriductive surgical in females with ovarian carcinoma in advanced stadium, and to define the role of this surgical for the survival of females with hepatic metastases.
This is a retrospective study. 164 females with ovarian cancer in IV stadium was examined. 64 females had hepatic metastasis. All patients had cytoriductive surgical.
The survival in the patients without hepatic metastasis was 38 months if the cytoreduction was very good; it was 18.3 months if there is residual disease. The survival in the patients with hepatic metastasis was 50.1 months if the cytoreduction was very good; it was 27 months if there is residual disease.
A very good surgical is very important for the survival of patients with ovarian cancer in advanced stadium. This is true also in the patients with hepatic metastases.
本研究旨在评估细胞减灭术对晚期卵巢癌女性患者的疗效，并确定该手术对肝转移女性患者生存的作用。
这是一项回顾性研究。对164例IV期卵巢癌女性患者进行了检查。64例患者有肝转移。所有患者均接受了细胞减灭术。
无肝转移患者若细胞减灭效果非常好，生存期为38个月；若有残留病灶，则为18.3个月。有肝转移患者若细胞减灭效果非常好，生存期为50.1个月；若有残留病灶，则为27个月。
对于晚期卵巢癌患者的生存，非常好的手术效果非常重要。对于有肝转移的患者也是如此。
